R

Retina Associates New Orleans | Jefferson Parish

Research site

(Unclaimed)

Location

4315 Houma Blvd, Suite 201, Metairie, Louisiana, United States of America

Site insights

Top conditions

Top treatments

EYP-1901

Iptacopan

ABP 938

APL-2

Aflibercept

FWY003

Eylea®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (SIENNA)

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling

Age-related Macular Degeneration (AMD)

Geographic Atrophy (GA)

Drug: Placebo

Drug: Pozelimab

Locations recently updated

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (...

Enrolling

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: FWY003

Drug: Placebo